United States · Exchanges & live quotes · Nasdaq

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2

Published by Nasdaq · United States 1 h ago

Key PointsViking is launching phase 3 trials for oral VK2735 after mixed phase 2 results.

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

Shipping Crisis Forces Asian Crude Buyers to Use Smaller Tankers

General Motors Topped Earnings Estimates. The Stock Is Sinking Anyway

BTT Price Up 3.22% on BitTorrent Buyback, AI Whitepaper

Cboe Global Markets

Tech Investors Bought the Dips

Developer’s guide to implementing MCP apps in Gemini